Table Of ContentAuthor Index
Andersen, D.O., Weber, N.D., Wood, S.G., De Clercq, E., see De Castro, L.M., 101
Hughes, B.G., Murray, B.K. and North, J.A., De Clercq, E., see Gordon, Y.J., 11
In vitro virucidal activity of selected anthraqui- De Clercq, E., see Maudgal, P.C., 93
nones and anthraquinone derivatives, 185 De Clercq, E., see Naesens, L., 53
Andrei, G., see Snoeck, R., | De Clercq, E., see Neyts, J., 41
Andries, K., Dewindt, B., Snoeks, J., Willebrords, De Clercq, E., see Palu, G., 115
R., Stokbroekx, R. and Lewi, P.J., A compara- De Clercq, E., see Snoeck, R., 1
tive test of fifteen compounds against all known Del Gobbo, V., Foli, A., Balestra, E., Villani, N.,
human rhinovirus serotypes as a basis for a more Marini, S., Perno, C.F. and Calio, R., Immuno-
rational screening program (Mini-Review), 213 modulatory activity of phosphonylmethoxyethyl
Andries, K., see White, E.L., 255 adenine (PMEA), a potent anti-HIV nucleoside
Ankel, H., see Bader, Th., 341 analogue, on in vivo murine models, 65
Araullo-Cruz, T., see Gordon, Y.J., 11 Desforges, B., see Sinet, M., 163
Awan, A.R., see Field, H.J., 29 Dewindt, B., see Andries, K., 213
Drach, J.C., see Nassiri, M.R., 135
Bader, Th., Yamada, Y. and Ankel, H., Antiviral Duncan, I.B., see Craig, J.C., 295
activity of the prostanoid clavulone II against Dutschman, G.E., see Kaufman, H.E., 225
vesicular stomatitis virus, 341
Balestra, E., see Del Gobbo, V., 65 Ebner, J.P., see Hoover, E.A., 77
Balzarini, J., see Naesens, L., 53 Eiseman, J.L., Yetter, R.A., Fredrickson, T.N.,
Balzarini, J., see Neyts, J., 41 Shapiro, 8.G., MacAuley, C. and Bilello, J.A.,
Balzarini, J., see Palu, G., 115 Effect of 3’azidothymidine administered in
Bilello, J.A., see Eiseman, J.L., 307 drinking water or by continuous infusion on
Birch, G.M., see Nassiri, M.R., 135 the development of MAIDS, 307
Bobek, M., see Kaufman, H.E., 225 Erzurum, S., see Gordon, Y.J., 11
Bohm, R., see Soike, K.F., 17
Buckheit, Jr., R.W., see White, E.L., 255 Field, H.J., Awan, A.R. and de la Fuente, R.,
Isolation of equine herpesvirus-1 mutants in the
Calio, R., see Del Gobbo, V., 65 presence of (S)-9-(3-hydroxy-2-phosphonyl-
Carpendale, M.T.F. and Freeberg, J.K., Ozone methoxypropyl)adenine: demonstration of resis-
inactivates HIV at noncytotoxic concentrations, tance in vitro and in vivo, 29
279 Foli, A., see Del Gobbo, V., 65
Ceruzzi, M., see Kmetz, M.E., 173 Fredrickson, T.N., see Eiseman, J.L., 307
Cheng, Y.C., see Kaufman, H.E., 225 Freeberg, J.K., see Carpendale, M.T.F., 279
Chirigos, M.A., see White, E.L., 255 de la Fuente, R., see Field, H.J., 29
Clausen, H., see Hansen, J.-E.S., 231 Fukuma, M., Seto, Y. and Yamase, T., In vitro
Cohen, J.S., Antisense oligodeoxynucleotides as antiviral activity of polyoxotungstate (PM-19)
antiviral agents (Mini-Review), 121 and other polyoxometalates against herpes
Coleman, L.A., see Nassiri, M.R., 135 simplex virus, 327
Colin, J.-N., see Sinet, M., 163
Craig, J.C., Duncan, I.B., Hockley, D., Grief, C., Gangemi, J.D., see De Castro, L.M., 101
Roberts, N.A. and Mills, J.S., Antiviral proper- Germany, J.M., see White, E.L., 255
ties of Ro 31-8959, an inhibitor of human Ghaffar, A., see De Castro, L.M., 101
immunodeficiency virus (HIV) proteinase, 295 Gordon, Y.J., Romanowski, E., Araullo-Cruz, T.,
Seaberg, L., Erzurum, S., Tolmam, R. and De
De Castro, L.M., Kern, E.R., De Clercq, E., Clercq, E., Inhibitory effect of (S)-HPMPC, (S)-
Ghaffar, A., Mayer, E.P., Vogt, P.E. and HPMPA, and 2’-nor-cyclic GMP on clinical
Gangemi, J.D., Phosphonylmethoxyalkyl pur- ocular adenoviral isolates is serotype-dependent
ine and pyrimidine derivatives for treatment of in vitro, 11
opportunistic cytomegalovirus and herpes sim- Grief, C., see Craig, J.C., 295
plex virus infections in murine AIDS, 101
362
Hansen, J.-E.S., Nielsen, C., Clausen, H., Mathie- the prophylaxis of retrovirus infection in vivo, 53
sen, L.R. and Nielsen, J.O., Effect of anti- Nakashima, H., see Otake, T., 241
carbohydrate antibodies on HIV infection in a Nassiri, M.R., Turk, S.R., Birch, G.M., Coleman,
monocytic cell line (U937), 231 L.A., Hudson, J.L., Pudlo, J.S., Townsend, L.B.
Hitchcock, M.J.M., see Soike, K.F., 17 and Drach, J.C., Activity of acyclic halogenated
Hockley, D., see Craig, J.C., 295 tubercidin analogs against human cytomegalo-
Holliday, J. and Williams, M.V., Inhibition of virus and in uninfected cells, 135
herpes simplex virus types 1 and 2 replication in Neyts, J., Snoeck, R., Balzarini, J. and De Clercq,
vitro by mercurithio analogs of deoxyuridine, E., Particular characteristics of the anti-human
197 cytomegalovirus activity of (S)-1-(3-hydroxy-2-
Hoover, E.A., Ebner, J.P., Zeidner, N.S. and phosphonylmethoxypropyl)cytosine (HPMPC)
Mullins, J.I., Early therapy of feline leukemia in vitro, 41
virus infection (FeLV-FAIDS) with 9-(2-phos- Neyts, J., see Snoeck, R., 1
phonylmethoxyethyl)adenine (PMEA), 77 Nicholas, J.A., see Rubino, K.L., 265
Huang, J.-L., see Soike, K.F., 17 Nielsen, C., see Hansen, J.-E.S., 231
Hudson, J.L., see Nassiri, M.R., 135 Nielsen, J.O., see Hansen, J.-E.S., 231
Hughes, B.G., see Andersen, D.O., 185 Nokta, M.A., see Shafik, H.M., 205
North, J.A., see Andersen, D.O., 185
Janssen, P.A.J., see White, E.L., 255
Otake, T., Miyano, K., Mori, H., Morimoto, M.,
Kaufman, H.E., Varnell, E.D., Cheng, Y.C., Ueba, N., Kunita, N., Nakashima, H. and
Bobek, M., Thompson, H.W. and Dutschman, Kurimura, T., Anti-HIV-1 activity of sulfated
G.E., Suppression of ocular herpes recurrences amphotericin B in vitro, 241
by a thymidine kinase inhibitor in squirrel
monkeys, 225 Palu, G., Stefanelli, S., Rassu, M., Parolin, C.,
Kern, E.R., see De Castro, L.M., 101 Balzarini, J. and De Clercq, E., Cellular uptake
Kmetz, M.E., Ceruzzi, M. and Schwartz, J., of phosphonylmethoxyalkylpurine derivatives
Vmw65 phosphorothioate oligonucleotides inhi- (Short Communication), 115
bit HSV KOS replication and Vmw65 protein Pancheva, S.N., Potentiating effect of ribavirin on
synthesis, 173 the anti-herpes activity of acyclovir, 151
Kunita, N., see Otake, T., 241 Parolin, C., see Palu, G., 115
Kurimura, T., see Otake, T., 241 Pauwels, R., see White, E.L., 255
Perno, C.F., see Del Gobbo, V., 65
Launay, O., see Sinet, M., 163 Pocidalo, J.-J., see Sinet, M., 163
Lewi, P.J., see Andries, K., 213 Pollard, R.B., see Shafik, H.M., 205
Pudlo, J.S., see Nassiri, M.R., 135
MacAuley, C., see Eiseman, J.L., 307
Marini, S., see Del Gobbo, V., 65 Rassu, M., see Palu, G., 115
Martin, J.C., see Soike, K.F., 17 Roberts, N.A., see Craig, J.C., 295
Mathiesen, L.R., see Hansen, J.-E.S., 231 Romanowski, E., see Gordon, Y.J., 11
Maudgal, P.C. and De Clercq, E., Effects of Ross, L.J., see White, E.L., 255
phosphonylmethoxyyalkyl-purine and -pyrimi- Rubino, K.L., Tarpley, W.G. and Nicholas, J.A.,
dine derivatives on TK+ and TK— HSV-1 Effects of a soluble CD4 and CD4-Pseudomonas
keratitis in rabbits, 93 exotoxin A chimeric protein on human periph-
Mayer, E.P., see De Castro, L.M., 101 eral blood lymphocytes: lymphocyte activation
Mills, J.S., see Craig, J.C., 295 and anti-HIV activity in vitro, 265
Miyano, K., see Otake, T., 241
Mori, H., see Otake, T., 241 Schols, D., see Snoeck, R., 1
Morimoto, M., see Otake, T., 241 Schwartz, J., see Kmetz, M.E., 173
Mullins, J.I., see Hoover, E.A., 77 Seaberg, L., see Gordon, Y.J., 11
Murray, B.K., see Andersen, D.O., 185 Seto, Y., see Fukuma, M., 327
Shafik, H.M., Nokta, M.A. and Pollard, R.B.,
Naesens, L., Balzarini, J. and De Clercq, E., Single- Recombinant human interferon beta ser protects
dose administration of 9-(2-phosphonylmethox- against zidovudine-induced genetic damage in
yethyl)jadenine (PMEA) and 9-(2-phosphonyl- AIDS patients, 205
methoxyethyl)-2,6-diaminopurine (PMEDAP) in Shannon, W.M., see White, E.L., 255
Shapiro, S.G., see Eiseman, J.L., 307 Turk, S.R., see Nassiri, M.R., 135
Sinet, M., Desforges, B., Launay, 0., Colin, J.-N.
and Pocidalo, J.-J., Factors influencing zidovu- Ueba, N., see Otake, T., 241
dine efficacy when administered at early stages of
Friend virus infection in mice, 163 Varnell, E.D., see Kaufman, H.E., 225
Snoeck, R., Schols, D., Andrei, G., Neyts, J. and Villani, N., see Del Gobbo, V., 65
De Clercq, E., Antiviral activity of anti-cytome- Vogt, P.E., see De Castro, L.M., 101
galovirus agents (HPMPC, HPMPA) assessed by
a flow cytometric method and DNA hybridiza- Weber, N.D., see Andersen, D.O., 185
tion technique, | White, E.L., Buckheit, Jr., R.W., Ross, L.J.,
Snoeck, R., see Neyts, J., 41 Germany, J.M., Andries, K., Pauwels, R.,
Snoeks, J., see Andries, K., 213 Janssen, P.A.J., Shannon, W.M. and Chirigos,
Soike, K.F., Huang, J.-L., Zhang, J.-Y., Bohm, R.., M.A., A TIBO derivative, R82913, is a potent
Hitchcock, M.J.M. and Martin, J.C., Evaluation inhibitor of HIV-1 reverse transcriptase with
of infrequent dosing regimens with (S)-1-[3- heteropolymer templates, 255
hydroxy-2-(phosphonylmethoxy)propyl]cytosine Willebrords, R., see Andries, K., 213
(S-HPMPC) on simian varicella infection in Williams, M.V., see Holliday, J., 197
monkeys, 17 Wood, S.G., see Andersen, D.O., 185
Stefanelli, S., see Palu, G., 115
Stokbroekx, R., see Andries, K., 213 Yamada, Y., see Bader, Th., 341
Yamase, T., see Fukuma, M., 327
Tarpley, W.G., see Rubino, K.L., 265 Yetter, R.A., see Eiseman, J.L., 307
Thompson, H.W., see Kaufman, H.E., 225
Tolmam, R., see Gordon, Y.J., 11 Zeidner, N.S., see Hoover, E.A., 77
Townsend, L.B., see Nassiri, M.R., 135 Zhang, J.-Y., see Soike, K.F., 17
Subject Index
AIDS, Human immunodeficiency virus type | rolopyrimidine, Nucieoside, 135
(HIV-1), Sulfated amphotericin B, Amphoteri- 7-Deaza adenosine, Cytomegalovirus, Herpes, Pyr-
cin B methyl ester, 243 rolopyrimidine, Nucleoside, 135
AIDS, Soluble CD4, sCD4-183, sCD4-PE40, HIV,
Pseudomonas exotoxin A, 267 DNA hybridization, Human cytomegalovirus, Flow
AIDS, ZDV, Interferon beta, Chromosomal da- cytometry, |
mage, 205 DNA integrity, Cytomegalovirus, HPMPC, 41
AZT, Animal model of HIV infection, Friend virus, Dendritic keratitis, Herpes simplex virus, Recurrent
Chemoprophylaxis, 163 ocular herpetic disease, Thymidine kinase, Virus
Acyclovir, Ribavirin, Combination chemotherapy, inhibitor, 225
HSV-1, PRV, Keratitis, 151 Drug development, Antisense, Oligonucleotide,
Adenovirus, (S)-HPMPC, (S)-HPMPA, 2’-nor-cyc- Translation arrest, Transcription arrest, 121
lic GMP, 11 dUTPase, Herpes simplex virus, Mercurithio-
Amphotericin B methyl ester, Human immunodefi- deoxyuridine analog, 197
ciency virus type | (HIV-1), Sulfated amphoter-
icin B, AIDS, 243 Emodin, Anthraquinone, Hypericin, Virucidal,
Animal model of HIV infection, AZT, Friend virus, Tween-80, 185
Chemoprophylaxis, 163 Endocytosis, HPMPA, PMEA, Cellular uptake,
Anthraquinone, Hypericin, Emodin, Virucidal, Nucleoside transport, 115
Tween-80, 185 Equine herpesvirus-1, EHV-1, Resistance, Phospho-
Antibody-dependent enhancement, HIV, U937, Neu- nyl, Nucleoside analog, Chemotherapy, 29
tralization, Carbohydrate, 231
Antiherpetic agent, Polyoxometalate, PM-19, Keg- FeLV-FAIDS, Feline leukemia virus, 9-(2-Phos-
gin-type structure, 327 phonylmethoxyethyl)adenine (PMEA), Immuno-
Antisense, Drug development, Oligonucleotide, deficiency, Retrovirus, 78
Translation arrest, Transcription arrest, 121 Feline leukemia virus, 9-(2-Phosphonylmethoxye-
Antiviral therapy, Azidothymidine, Zidovudine, thyl)adenine (PMEA), Immunodeficiency, Ret-
MAIDS, LP-BM5, MuLV, 307 rovirus, Fe_LV-FAIDS, 78
Azidothymidine, Zidovudine, MAIDS, Antiviral Flow cytometry, Human cytomegalovirus, DNA
therapy, LP-BMS, MuLV, 307 hybridization, |
Friend virus, AZT, Animal model of HIV infection,
BVDU, HSV-1 keratitis, TK— HSV-1, HPMPA, Chemoprophylaxis, 163
HPMPC, PMEA, Phosphonylmethoxyalkyl de-
rivative, 93 HIV, Human immunodeficiency virus, Moloney
murine sarcoma virus, MSV, Single dose admin-
Carbohydrate, HIV, U937, Neutralization, Anti- istration, 53
body-dependent enhancement, 231 HIV, Ozone, Noncytotoxic, Virus inhibitor, 279
Cellular uptake, HPMPA, PMEA, Endocytosis, HIV, Proteinase, Inhibitor, 295
Nucleoside transport, 115 HIV, Soluble CD4, sCD4-183, sCD4-PE40, AIDS,
Chemoprophylaxis, AZT, Animal model of HIV Pseudomonas exotoxin A, 265
infection, Friend virus, 163 HIV, U937, Neutralization, Antibody-dependent
Chemotherapy, Equine herpesvirus-1, EHV-1, Re- enhancement, Carbohydrate, 231
sistance, Phosphonyl, Nucleoside analog, 29 HIV-1, TIBO, HIV-2, Reverse transcriptase, Novel
Chromosomal damage, ZDV, Interferon beta, RNA template, 255
AIDS, 205 HIV-2, TIBO, HIV-1, Reverse transcriptase, Novel
Clavulone, Vesicular stomatitis virus, Prostaglan- RNA template, 255
din, 341 HPMPA, HSV-1 keratitis, TK— HSV-1, BVDU,
Combination chemotherapy, Acyclovir, Ribavirin, HPMPC, PMEA, Phosphonylmethoxyalkyl de-
HSV-1, PRV, Keratitis, 151 rivative, 93
Cytomegalovirus, HPMPC, DNA integrity, 41 HPMPA, PMEA, Cellular uptake, Endocytosis,
Cytomegalovirus, Herpes, 7-Deaza adenosine, Pyr- Nucleoside transport, 115
366
HPMPC therapy, Murine acquired immunodefi- therapy, LP-BM5, MuLV, 307
ciency syndrome, MAIDS, Opportunistic infec- MAIDS, Murine acquired immunodeficiency syn-
tion, PMEA therapy, 102 drome, Opportunistic infection, HPMPC ther-
HPMPC, Cytomegalovirus, DNA integrity, 41 apy, PMEA therapy, 102
HPMPC, HSV-1 keratitis, TK— HSV-1, BVDU, MSV, Human immunodeficiency virus, HIV,
HPMPA, PMEA, Phosphonylmethoxyalky] de- Moloney murine sarcoma virus, Single dose
rivative, 93 administration, 53
HPMPC, Simian varicella virus, Monkey, 17 Mercurithio-deoxyuridine analog, Herpes simplex
HSV-1 keratitis, TK — HSV-1, BVDU, HPMPA, virus, d(UTPase, 197
HPMPC, PMEA, Phosphonylmethoxyalkyl de- Moloney murine sarcoma virus, Human immunode-
rivative, 93 ficiency virus, HIV, MSV, Single dose adminis-
HSV-1, Acyclovir, Ribavirin, Combination chemo- tration, 53
therapy, PRV, Keratitis, 151 Monkey, Simian varicella virus, HPMPC, 17
Herpes simplex virus, dUTPase, Mercurithio-deox- MuLV, Azidothymidine, Zidovudine, MAIDS,
yuridine analog, 197 Antiviral therapy, LP-BM5, 307
Herpes simplex virus, Dendritic keratitis, Recurrent Murine acquired immunodeficiency syndrome,
ocular herpetic disease, Thymidine kinase, Virus MAIDS, Opportunistic infection, HPMPC ther-
inhibitor, 225 apy, PMEA therapy, 102
Herpes, Cytomegalovirus, 7-Deaza adenosine,
Pyrrolopyrimidine, Nucleoside, 135 NK cytotoxicity, Nucleoside analog, 9-(2-phospho-
Human cytomegalovirus, DNA hybridization, Flow nylmethoxyethyl)adenine, Interferon, Interleu-
cytometry, | kin-1, Interleukin-2, 65
Human immunodeficiency virus, HIV, Moloney Neutralization, HIV, U937, Antibody-dependent
murine sarcoma virus, MSV, Single dose admin- enhancement, Carbohydrate, 231
istration, 53 Noncytotoxic, HIV, Ozone, Virus inhibitor, 279
Human immunodeficiency virus type 1 (HIV-1), Novel RNA template, TIBO, HIV-1, HIV-2,
Sulfated amphotericin B, Amphotericin B Reverse transcriptase, 255
methyl ester, AIDS, 243 Nucleoside analog, Equine herpesvirus-1, EHV-1,
Hypericin, Anthraquinone, Emodin, Virucidal, Resistance, Phosphonyl, Chemotherapy, 29
Tween-80, 185 Nucleoside analog, 9-(2-phosphonylmethoxye-
thyl)adenine, NK cytotoxicity, Interferon, Inter-
Immunodeficiency, Feline leukemia virus, 9-(2- leukin-1, Interleukin-2, 65
Phosphonylmethoxyethyl)adenine (PMEA), Ret- Nucleoside transport, HPMPA, PMEA, Cellular
rovirus, Fe_LV-FAIDS, 78 uptake, Endocytosis, 115
Inhibitor, HIV, Proteinase, 295 Nucleoside, Cytomegalovirus, Herpes, 7-Deaza
Interferon, Nucleoside analog, 9-(2-phosphonylme- adenosine, Pyrrolopyrimidine, 135
thoxyethyl)adenine, NK cytotoxicity, Interleu-
kin-1, Interleukin-2, 65 Oligodeoxynucleotide, Phosphorothioate modifica-
Interferon beta, ZDV, Chromosomal damage, tion, Protein synthesis inhibition, Replication
AIDS, 205 inhibition, 173
Interleukin-1, Nucleoside analog, 9-(2-phosphonyl- Oligonucleotide, Antisense, Drug development,
methoxyethyl)adenine, NK cytotoxicity, Inter- Translation arrest, Transcription arrest, 121
feron, Interleukin-2, 65 Opportunistic infection, Murine acquired immuno-
Interleukin-2, Nucleoside analog, 9-(2-phosphonyl- deficiency syndrome, MAIDS, HPMPC therapy,
methoxyethyl)adenine, NK cytotoxicity, Inter- PMEA therapy, 102
feron, Interleukin-1, 65 Ozone, HIV, Noncytotoxic, Virus inhibitor, 279
Keratitis, Acyclovir, Ribavirin, Combination che- 9-(2-Phosphonylmethox yethyl)adenine (PMEA), Fe-
motherapy, HSV-1, PRV, 15i line leukemia virus, Immunodeficiency, Retro-
Keggin-type structure, Polyoxometalate, PM-19, virus, FeLV-FAIDS, 78
Antiherpetic agent, 327 9-(2-phosphonylmethoxyethyl)adenine, Nucleoside
analog, NK cytotoxicity, Interferon, Interleu-
LP-BMS5, Azidothymidine, Zidovudine, MAIDS, kin-1, Interleukin-2, 65
Antiviral therapy, MuLV, 307
PM-19, Polyoxometalate, Keggin-type structure,
MAIDS, Azidothymidine, Zidovudine, Antiviral Antiherpetic agent, 327
367
PMEA therapy, Murine acquired immunodeficien- Screening, antiviral, Rational screening program,
cy syndrome, MAIDS, Opportunistic infection, Rhinovirus, 213
HPMPC therapy, 102 (S)-HPMPA, 2’-nor-cyclic GMP, (S)-HPMPC,
PMEA, HPMPA, Cellular uptake, Endocytosis, Adenovirus, | 1
Nucleoside transport, 115 (S)-HPMPC, (S)-HPMPA, 2’-nor-cyclic GMP,
PMEA, HSV-1 keratitis, TK— HSV-1, BVDU, Adenovirus, 11
HPMPA, HPMPC, Phosphonylmethoxyalkyl sCD4-183, Soluble CD4, sCD4-PE40, AIDS, HIV,
derivative, 93 Pseudomonas exotoxin A, 265
PRV, Acyclovir, Ribavirin, Combination chemo- sCD4-PE40, Soluble CD4, sCD4-183, AIDS, HIV,
therapy, HSV-1, Keratitis, 151 Pseudomonas exotoxin A, 265
Phosphonyl, Equine herpesvirus-1, EHV-1, Resis- Simian varicella virus, HPMPC, Monkey, 17
tance, Nucleoside analog, Chemotherapy, 29 Single dose administration, Human immunodefi-
Phosphonyimethoxyalkyl derivative, HSV-1 kerati- ciency virus, HIV, Moloney murine sarcoma
tis, TK— HSV-1, BVDU, HPMPA, HPMPC, virus, MSV, 53
PMEA, 93 Soluble CD4, sCD4-183, sCD4-PE40, AIDS, HIV,
Phosphorothioate modification, Oligodeoxynucleo- Pseudomonas exotoxin A, 265
tide, Protein synthesis inhibition, Replication Sulfated amphotericin B, Human immunodeficiency
inhibition, 173 virus type 1 (HIV-1), Amphotericin B methyl
Polyoxometalate, PM-19, Keggin-type structure, ester, AIDS, 243
Antiherpetic agent, 327
Prostaglandin, Vesicular stomatitis virus, Clavu- TIBO, HIV-1, HIV-2, Reverse transcriptase, Novel
lone, 341 RNA template, 255
Protein synthesis inhibition, Phosphorothioate mod- TK— HSV-1, HSV-1 keratitis, BVDU, HPMPA,
ification, Oligodeoxynucleotide, Replication in- HPMPC, PMEA, Phosphonylmethoxyalkyl de-
hibition, 173 rivative, 93
Proteinase, HIV, Inhibitor, 295 Thymidine kinase, Dendritic keratitis, Herpes
Pseudomonas exotoxin A, Soluble CD4, sCD4-183, simplex virus, Recurrent ocular herpetic dis-
sCD4-PE40, AIDS, HIV, 265 ease, Virus inhibitor, 225
Pyrrolopyrimidine, Cytomegalovirus, Herpes, 7- Transcription arrest, Antisense, Drug development,
Deaza adenosine, Nucleoside, 135 Oligonucleotide, Translation arrest, 121
Translation arrest, Antisense, Drug development,
Rational screening program, Rhinovirus, Screening, Oligonucleotide, Transcription arrest, 121
antiviral, 213 Tween-80, Anthraquinone, Hypericin, Emodin,
Recurrent ocular herpetic disease, Dendritic kerati- Virucidal, 185
tis, Herpes simplex virus, Thymidine kinase,
Virus inhibitor, 225 U937, HIV, Neutralization, Antibody-dependent
Replication inhibition, Phosphorothioate modifica- enhancement, Carbohydrate, 231
tion, Oligodeoxynucleotide, Protein synthesis
inhibition, 173 Vesicular stomatitis virus, Prostaglandin, Clavu-
Resistance, Equine herpesvirus-1, EHV-1, Phos- lone, 341
phonyl, Nucleoside analog, Chemotherapy, 29 Virucidal, Anthraquinone, Hypericin, Emodin,
Retrovirus, Feline leukemia virus, 9-(2-Phosphonyl- Tween-80, 185
methoxyethyl)adenine (PMEA), Immunodefi- Virus inhibitor, Dendritic keratitis, Herpes simplex
ciency, Fe_LV-FAIDS, 78 virus, Recurrent ocular herpetic disease, Thymi-
Reverse transcriptase, TIBO, HIV-1, HIV-2, Novel dine kinase, 225
RNA template, 255 Virus inhibitor, HIV, Ozone, Noncytotoxic, 279
Rhinovirus, Rational screening program, Screening,
antiviral, 213 ZDV, Interferon beta, Chromosomal damage,
Ribavirin, Acyclovir, Combination chemotherapy, AIDS, 205
HSV-1, PRV, Keratitis, 151 Zidovudine, Azidothymidine, MAIDS, Antiviral
therapy, LP-BM5, MuLV, 307
